Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on May 13, 2024. The filing serves to announce the Company's results of operations for the fiscal quarter ended March 31, 2024, and to provide updates on its antiviral drug development programs.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing indicates the announcement of quarterly results and program updates but does not explicitly detail material changes versus the prior comparable period within the text provided.
Guidance, Outlook, and Risks
Management provided updates on antiviral drug development programs. The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 13, 2024) for specific Q1 2024 financial figures.
- Verify the status and timeline of the Company's antiviral drug development programs.
- Confirm cash runway and liquidity position as detailed in the full press release.
- Check for any new risk factors or contingencies disclosed in the accompanying press release.